For the millions of high-risk cardiovascular patients who fail to reach guideline-recommended LDL cholesterol targets on statins alone, the question of what comes next has long lacked a definitive answer from rigorous comparative trials. This large Phase 4 randomized study provides some of the clearest head-to-head evidence yet that RNA-interference therapy can dramatically close that treatment gap.

The VICTORION-Difference trial enrolled 1,770 adults with hypercholesterolaemia classified as high or very high cardiovascular risk, randomizing them 1:1 to either inclisiran sodium (300 mg subcutaneous injection) or individually optimized lipid-lowering therapy anchored by open-label rosuvastatin uptitration. Both arms aimed to reach each participant's personalized LDL-C target. At the primary endpoint of Day 90, 84.9% of inclisiran recipients had achieved their individual LDL-C goal compared with just 31.0% in the statin-optimization arm — an odds ratio of 12.09 that is statistically and clinically striking. The inclisiran arm also demonstrated superior mean LDL-C reduction and a favorable muscle-related adverse event profile relative to the uptitrated statin group.

Inclisiran works by silencing hepatic PCSK9 messenger RNA via small interfering RNA (siRNA), reducing PCSK9 protein synthesis and thereby upregulating LDL receptor recycling on hepatocytes. Unlike monoclonal PCSK9 antibodies such as evolocumab or alirocumab, which require monthly or bimonthly dosing, inclisiran is administered just twice yearly after an initial dose, a feature with meaningful adherence implications. This trial's contribution lies in directly comparing the siRNA approach not to placebo alone but to real-world-style statin intensification — a more pragmatically relevant comparator. Key limitations include the 90-day primary endpoint, which cannot speak to hard cardiovascular outcomes, and the open-label rosuvastatin arm introduces potential performance bias. Whether this LDL-C advantage translates to proportional reductions in myocardial infarction or stroke over years remains the critical unanswered question. Overall, this is a confirmatory but meaningfully practice-informing result for clinicians managing statin-insufficient high-risk patients.